Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOT201 in Advanced/Metastatic Solid Tumors
NCT06163391Phase 1Active, not recruiting
- Sponsor
- SOTIO Biotech
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Immunomodulatory ADCs, Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of sot201 in solid tumor, sponsored by SOTIO Biotech. Primary endpoints: Treatment-Emergent Adverse Events and Dose-Limiting Toxicities at 28 days. Started May 2024; status: active, not recruiting.
02
Drugs
sot201
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06163391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06163391.